Neurocrine Biosciences (NBIX): next trial readout expected around 2029-09-06
Trials that could report in the next 12 months: 1BiopharmaCTG
Catalyst timeline
Dates are estimated from each trial's registered completion date — none are FDA decision dates. Counts trials that fit our shared poll budget, not everything NBIX is running — see methodology.
- 2029-09-06in 159wPharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Pipeline
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participa… | Phase 2 | Active Not Recruitingenrolled, still running | 2029-09-06 | NCT07187375 |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctiv… | Phase 3 | Recruitingstill enrolling patients | NCT06786624 | |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-10… | Phase 3 | Recruitingstill enrolling patients | NCT06911112 | |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-10… | Phase 3 | Recruitingstill enrolling patients | NCT06963021 | |
| NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults Wit… | Phase 3 | Recruitingstill enrolling patients | NCT06963034 | |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 a… | Phase 3 | Recruitingstill enrolling patients | NCT06966401 | |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Particip… | Phase 4 | Recruitingstill enrolling patients | NCT07105111 | |
| NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults Wit… | Phase 3 | Recruitingstill enrolling patients | NCT07114874 |
+ 8 more tracked trials
| Program | Phase | Status | Primary completion | Trial |
|---|---|---|---|---|
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunc… | Phase 3 | Recruitingstill enrolling patients | NCT07196501 | |
| Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophr… | Phase 3 | Recruitingstill enrolling patients | NCT07227818 | |
| NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults Wit… | Phase 3 | Recruitingstill enrolling patients | NCT07105098 | |
| Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Ad… | Phase 2 | Recruitingstill enrolling patients | NCT07365462 | |
| An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568… | Phase 2 | Recruitingstill enrolling patients | NCT07288320 | |
| Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | Phase 2 | Recruitingstill enrolling patients | NCT07288333 | |
| Long-term Study to Evaluate Safety and Tolerability of Valbenazine in … | Phase 3 | Enrolling By Invitation | NCT06312189 | |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinece… | Phase 2 | Not Yet Recruitingnot open yet | NCT07536269 |
Status-change history
Every ClinicalTrials.gov change recorded for NBIX's trials — a running history no other tracker shows.
No status changes detected yet for this ticker.
Frequently asked
When is NBIX's next PDUFA date?
No disclosed PDUFA date is currently tracked for this ticker.
What phase is NBIX's lead program in?
Phase 3 — recruiting.
Where does this data come from?
ClinicalTrials.gov v2 API (trial status + diffs) and company 8-K/press-release disclosures (PDUFA dates). Every number links to its source.